DLD
Dihydrolipoyl dehydrogenase, mitochondrial
Also known as: DLDH, DLDH_HUMAN, E3, GCSL, LAD, OGDC-E3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P09622
- Gene
- DLD
- Ensembl
- ENSG00000091140
- Chromosome
- 7
- Canonical length
- 509 aa
- Protein class
- Citric acid cycle related proteins, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Mitochondria,Principal piece
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the class-I pyridine nucleotide-disulfide oxidoreductase family. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions. In homodimeric form, the encoded protein functions as a dehydrogenase and is found in several multi-enzyme complexes that regulate energy metabolism. However, as a monomer, this protein can function as a protease. Mutations in this gene have been identified in patients with E3-deficient maple syrup urine disease and lipoamide dehydrogenase deficiency. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2014]
Canonical amino-acid sequenceUniProt
509 residues, UniProt reviewed canonical sequence.
>P09622|DLD
1 MQSWSRVYCS LAKRGHFNRI SHGLQGLSAV PLRTYADQPI DADVTVIGSG PGGYVAAIKA
61 AQLGFKTVCI EKNETLGGTC LNVGCIPSKA LLNNSHYYHM AHGKDFASRG IEMSEVRLNL
121 DKMMEQKSTA VKALTGGIAH LFKQNKVVHV NGYGKITGKN QVTATKADGG TQVIDTKNIL
181 IATGSEVTPF PGITIDEDTI VSSTGALSLK KVPEKMVVIG AGVIGVELGS VWQRLGADVT
241 AVEFLGHVGG VGIDMEISKN FQRILQKQGF KFKLNTKVTG ATKKSDGKID VSIEAASGGK
301 AEVITCDVLL VCIGRRPFTK NLGLEELGIE LDPRGRIPVN TRFQTKIPNI YAIGDVVAGP
361 MLAHKAEDEG IICVEGMAGG AVHIDYNCVP SVIYTHPEVA WVGKSEEQLK EEGIEYKVGK
421 FPFAANSRAK TNADTDGMVK ILGQKSTDRV LGAHILGPGA GEMVNEAALA LEYGASCEDI
481 ARVCHAHPTL SEAFREANLA ASFGKSINFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DLD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 229 nTPM
Expression across tissuesHPA
Tissue
- tongue: 229 nTPM
- skeletal muscle: 216 nTPM
- heart muscle: 155 nTPM
- kidney: 109 nTPM
- parathyroid gland: 85 nTPM
- liver: 84 nTPM
Single-cell type
- parietal cells: 400 nCPM
- epicardial cells: 264 nCPM
- neutrophil progenitors: 152 nCPM
- cytotrophoblasts: 136 nCPM
- syncytiotrophoblasts: 125 nCPM
- adipocytes: 124 nCPM
Immune cell
- basophil: 76 nTPM
- eosinophil: 72 nTPM
- non-classical monocyte: 67 nTPM
- myeloid DC: 44 nTPM
- intermediate monocyte: 43 nTPM
- NK-cell: 38 nTPM
Brain region
- choroid plexus: 48 nTPM
- midbrain: 31 nTPM
- hypothalamus: 30 nTPM
- cerebellum: 30 nTPM
- medulla oblongata: 29 nTPM
- pons: 29 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DLD.
Disease | AllUniProt
Conditions DLD is implicated in, by any mechanism.
- Dihydrolipoamide dehydrogenase deficiency (DLDD) MIM:246900
Disease | GeneticClinVar
139 pathogenic / likely-pathogenic of 742 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Pyruvate dehydrogenase E3 deficiency
- Inborn genetic diseases
- DLD-related disorder
- Thyroid cancer, nonmedullary, 1
- See cases
ReferencesPubMed · IEDB
Publications for DLD from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
- Proteomic identification of dihydrolipoamide dehydrogenase as a target of autoantibodies in patients with endometrial cancer.
2014 · Anticancer Res · RCR 0.9 · 26 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.55
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 1.1
- DepMap mean gene effect
- -0.24
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 11% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 2-oxoglutarate decarboxylation to succinyl-CoA
- 2-oxoglutarate metabolic process
- branched-chain alpha-keto acid decarboxylation to branched-chain acyl-CoA
- branched-chain amino acid catabolic process
- gastrulation
- mitochondrial electron transport, NADH to ubiquinone
- proteolysis
- pyruvate decarboxylation to acetyl-CoA
- regulation of membrane potential
- sperm capacitation
- L-lysine catabolic process to acetyl-CoA
Molecular functions
- flavin adenine dinucleotide binding
- dihydrolipoyl dehydrogenase (NADH) activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Pyridine nucleotide-disulphide oxidoreductase, class I
- Pyridine nucleotide-disulphide oxidoreductase, dimerisation domain
- Pyridine nucleotide-disulphide oxidoreductase, class I, active site
- FAD/NAD-linked reductase, dimerisation domain superfamily
- FAD/NAD(P)-binding domain
- FAD/NAD(P)-binding domain superfamily
- Pyridine nucleotide-disulphide oxidoreductase, dimerisation domain
- Pyridine nucleotide-disulphide oxidoreductase
- Dihydrolipoamide dehydrogenase
- Class-I pyridine nucleotide-disulfide oxidoreductase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DLD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DLD as an antibody target. Whether an autoantibody or antibody against DLD could matter depends on whether native DLD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DLD is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DLD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...